Niacin (Niaspan) adverse events in AIM-HIGH, HPS2-THRIVENiacin (Niaspan) adverse events in AIM-HIGH, HPS2-THRIVE

AIM-HIGH researchers have yet to publish a detailed post hoc analysis of adverse events related to niacin therapy, but the investigators do not believe there was a real risk of bleeding or infection observaed with the proprietary extended-release niacin in the trial. However, the HPS2-THRIVE team believes the results of AIM-HIGH support their conclusions about niacin's off-target risks. Heartwire
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news